研究と業績
ホーム > 研究と業績> 主な研究業績

主な研究業績

2019年度

  1. Shibata W, Niki M, Sato K, Fujimoto H, Yamada K, Watanabe T, Miyazaki Y, Asai K, Obata Y, Tachibana T, Kawaguchi T, Kaneko Y, Kakeya H. Detection of Rhizopus-specific antigen in human and murine serum and bronchoalveolar lavage. Med Mycol. Epub ahead of print, 2020.
  2. Imoto W, Yamada K, Yamairi K, Shibata W, Namikawa H, Yukawa S, Yoshii N, Nakaie K, Hirose A, Koh H, Watanabe T, Asai K, Nakamae H, Kaneko Y, Kawaguchi T, Hino M, Kakeya H. Clinical Characteristics of Rapidly Progressive Fatal Hemorrhagic Pneumonia Caused by Stenotrophomonas maltophilia. Intern Med. 59(2):193-198, 2020.
  3. Kawaguchi H, Yamada K, Imoto W, Yamairi K, Shibata W, Namikawa H, Yoshii N, Nakaie K, Okada Y, Fujita A, Shinoda Y, Nakamura Y, Kaneko Y, Nagayama K, Kakeya H. The effects of antifungal stewardship programs at a tertiary-care teaching hospital in Japan. J Infect Chemother. 25(6):458-462, 2019.
  4. Namikawa H, Niki M, Niki M, Yamada K, Nakaie K, Sakiyama A, Oinuma KI, Tsubouchi T, Tochino Y, Takemoto Y, Kaneko Y, Shuto T, Kakeya H. Clinical and virulence factors related to the 30-day mortality of Klebsiella pneumoniae bacteremia at a tertiary hospital: a case-control study. Eur J Clin Microbiol Infect Dis. 38(12):2291-2297, 2019.
  5. Yamada K, Imoto W, Yamairi K, Shibata W, Namikawa H, Yoshii N, Fujimoto H, Nakaie K, Okada Y, Fujita A, Kawaguchi H, Shinoda Y, Nakamura Y, Kaneko Y, Yoshida H, Kakeya H. The intervention by an antimicrobial stewardship team can improve clinical and microbiological outcomes of resistant gram-negative bacteria. J Infect Chemother. 25(12):1001-1006, 2019.
  6. Namikawa H, Yamada K, Sakiyama A, Imoto W, Yamairi K, Shibata W, Yoshii N, Niki M, Nakaie K, Oinuma KI, Tsubouchi T, Niki M, Tochino Y, Takemoto Y, Kaneko Y, Shuto T, Kakeya H. Clinical characteristics of bacteremia caused by hypermucoviscous Klebsiella pneumoniae at a tertiary hospital. Diagn Microbiol Infect Dis. 95(1):84-88, 2019.
  7. Namikawa H, Oinuma KI, Sakiyama A, Tsubouchi T, Tahara YO, Yamada K, Niki M, Takemoto Y, Miyata M, Kaneko Y, Shuto T, Kakeya H. Discovery of anti-mucoviscous activity of rifampicin and its potential as a candidate antivirulence agent against hypervirulent Klebsiella pneumoniae. Int J Antimicrob Agents. 54(2):167-175, 2019.
  8. Oinuma KI, Suzuki M, Nakaie K, Sato K, Saeki K, Sakiyama A, Takizawa E, Niki M, Niki M, Yamada K, Shibayama K, Kakeya H, Kaneko Y. Genome-based epidemiological analysis of 13 Acinetobacter strains isolated from blood cultures of hospitalized patients from a university hospital in Japan. Jpn J Infect Dis. 72(4):274-280, 2019.
  9. Namikawa H, Yamada K, Yamairi K, Shibata W, Fujimoto H, Takizawa E, Niki M, Nakaie K, Oinuma KI, Niki M, Takemoto Y, Kaneko Y, Shuto T, Kakeya H. Mortality caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae bacteremia; a case control study: alert to Enterobacteriaceae strains with high minimum inhibitory concentrations of piperacillin/tazobactam. Diagn Microbiol Infect Dis. 94(3):287-292, 2019.
  10. Yamakawa H, Kosai K, Akamatsu N, Matsuda J, Kaku N, Uno N, Morinaga Y, Hasegawa H, Tsubouchi T, Kaneko Y, Miyazaki T, Izumikawa K, Mukae H, Yanagihara K. Molecular and epidemiological analysis of IMP-1 metallo-β-lactamase-producing Klebsiella pneumoniae in a tertiary care hospital in Japan. J Infect Chemother. 25(4):240-6, 2019.
  11. Yamairi K, Ido K, Nakamura S, Niki M, Imoto W, Shibata W, Namikawa H, Fujimoto H, Yamada K, Nakamae H, Hino M, Kaneko Y, Miyazaki Y, Kakeya H. Successful treatment of invasive pulmonary aspergillosis caused by Aspergillus felis, a cryptic species within the Aspergillus section Fumigati: A case report. J Infect Chemother. 25(4):307-10, 2019.

2018年度

  1. Ohara Y, Ozeki Y, Tateishi Y, Mashima T, Arisaka F, Tsunaka Y, Fujiwara Y, Nishiyama A, Yoshida Y, Kitadokoro K, Kobayashi H, Kaneko Y, Nakagawa I, Maekura R, Yamamoto S, Katahira M, Matsumoto S. Significance of a histone-like protein with its native structure for the diagnosis of asymptomatic tuberculosis. PLoS One. 13(10):e0204160, 2018.
  2. Goss CH, Kaneko Y, Khuu L, Anderson GD, Ravishankar S, Aitken ML, Lechtzin N, Zhou G, Czyz DM, Mclean K, Olakanmi O, Shuman HA, Teresi M, Wilhelm E, Caldwell E, Salipante SJ, Hornick DB, Siehnel RJ, Becker L, Britigan BE, Singh PK. Gallium disrupts bacterial iron metabolism and has therapeutic effects in mice and humans with lung infections. Sci Transl Med. 10(460). pii: eaat7520, 2018.
  3. Kaneko Y, Oinuma KI, Terachi T, Arimura Y, Niki M, Yamada K, Kakeya H, Mizutani T. Successful Treatment of Intestinal Mycosis Caused by a Simultaneous Infection with Lichtheimia ramosa and Aspergillus calidoustus. Intern Med. 57(16):2421-2424, 2018.
  4. Niki M, Yoshiyama T, Miyamoto Y, Okumura M, Niki M, Oinuma KI, Kaneko Y, Matsumoto S, Sasaki Y, Ogata H, Goto H, Kudoh S, Hoshino Y. Longitudinal Evaluation of Humoral Immunity and Bacterial and Clinical Parameters Reveals That Antigen-Specific Antibodies Suppress Inflammatory Responses in Active Tuberculosis Patients. J Immunol Res. 2018:4928757, 2018.
  5. Inoue M, Niki M, Ozeki Y, Nagi S, Chadeka EA, Yamaguchi T, Osada-Oka M, Ono K, Oda T, Mwende F, Kaneko Y, Matsumoto M, Kaneko S, Ichinose Y, Njenga SM, Hamano S, Matsumoto S. High-density lipoprotein suppresses tumor necrosis factor alpha production by mycobacteria-infected human macrophages. Sci Rep. 8(1):6736, 2018.

2017年度

  1. Tsubouchi T, Kaneko Y. Draft Genome Sequence of the Arsenic-Resistant Bacterium Brevundimonas denitrificans TAR-002(T). Genome Announc. 5(47). pii: e01326-17, 2017.
  2. Namikawa H, Yamada K, Shibata W, Fujimoto H, Takizawa E, Niki M, Nakaie K, Nakamura Y, Oinuma KI, Niki M, Takemoto Y, Kaneko Y, Shuto T, Kakeya H. Clinical Characteristics and Low Susceptibility to Daptomycin in Enterococcus faecium Bacteremia. Tohoku J Exp Med. 243(3):211-218, 2017.
  3. Sato K, Oinuma K, Niki M, Yamagoe S, Miyazaki Y, Asai K, Yamada K, Hirata K, Kaneko Y, Kakeya H. Identification of a novel Rhizopus-specific antigen by screening with a signal sequence trap and evaluation as a possible diagnostic marker of mucormycosis. Med Mycol. 55(7):713-719, 2017.
  4. Niki M, Yoshiyama T, Miyamoto Y, Okumura M, Niki M, Oinuma K, Kaneko Y, Matsumoto S, Sasaki Y, Ogata H, Goto H, Kudoh S, Hoshino Y. Longitudinal evaluation of humoral immunity and bacterial and clinical parameters reveals that antigen-specific antibodies suppress inflammatory responses in active tuberculosis patients. J Immunol Res. in press, 2017.
  5. Yamada K, Namikawa H, Fujimoto H, Nakaie K, Takizawa E, Okada Y, Fujita A, Kawaguchi H, Nakamura Y, Abe J, Kaneko Y, Kakeya H. Clinical Characteristics of Methicillin-resistant Coagulase-negative Staphylococcal Bacteremia in a Tertiary Hospital. Intern Med. 56(7):781-5, 2017.
  6. Namikawa H, Yamada K, Fujimoto H, Oinuma KI, Tochino Y, Takemoto Y, Kaneko Y, Shuto T, Kakeya H. Clinical Characteristics of Bacteremia Caused by Extended-spectrum Beta-lactamase-producing Escherichia coli at a Tertiary Hospital. Intern Med. 56(14):1807-15, 2017.

2016年度

  1. Totani T, Nishiuchi Y, Tateishi Y, Yoshida Y, Kitanaka H, Niki M, Kaneko Y, Matsumoto S. Effects of nutritional and ambient oxygen condition on biofilm formation in Mycobacterium avium subsp. hominissuis via altered glycolipid expression. Sci Rep. 7:41775, 2017.
  2. Nakaie K, Yamada K, Park K, Nakamura Y, Okada Y, Fujita A, Fujimoto H, Kaneko Y, Kakeya H. Effectiveness of weekly polymerase chain reaction-based open reading frame typing analysis of all newly isolated methicillin-resistant Staphylococcus aureus strains for controlling nosocomial infections. J Infect Chemother. 22(11):733-7, 2016.
  3. Namikawa H, Yamada K, Fujimoto H, Oinuma K, Tochino Y, Takemoto Y, Kaneko Y, Shuto T, Kakeya H. Two unusual cases of successful treatment of hypermucoviscous Klebsiella pneumoniae invasive syndrome. BMC Infect Dis. 16(1):680, 2016.
  4. Oinuma K, Suzuki M, Sato K, Nakaie K, Niki M, Takizawa E, Niki M, Shibayama K, Yamada K, Kakeya H, Kaneko Y. Genome sequence of an Acinetobacter baumannii strain carrying three acquired carbapenemase genes. Genome Announc. 4(6). pii: e01290-16, 2016.
  5. Takizawa E, Yamada K, Oinuma K, Sato K, Niki M, Namikawa H, Fujimoto H, Asai K, Kaneko Y, Kakeya H. An Intrinsic Strain of Colistin-resistant Acinetobacter Isolated from a Japanese Patient. Intern Med. 55(16):2301-6, 2016.

2015年度

  1. Urai M, Kaneko Y, Ueno K, Okubo Y, Aizawa T, Fukazawa H, Sugita T, Ohno H, Shibuya K, Kinjo Y, Miyazaki Y. Evasion of Innate Immune Responses by the Highly Virulent Cryptococcus gattii by Altering Capsule Glucuronoxylomannan Structure. Front Cell Infect Microbiol. 5:101, 2016.
  2. Niki M, Suzukawa M, Akashi S, Nagai H, Ohta K, Inoue M, Niki M, Kaneko Y, Morimoto K, Kurashima A, Kitada S, Matsumoto S, Suzuki K, Hoshino Y. Evaluation of humoral immunity to Mycobacterium tuberculosis-specific antigens for correlation with clinical status and effective vaccine development. J Immunol Res. 2015:527395, 2015.
  3. Ueno K, Kinjo Y, Okubo Y, Aki K, Urai M, Kaneko Y, Shimizu K, Wang DN, Okawara A, Nara T, Ohkouchi K, Mizuguchi Y, Kawamoto S, Kamei K, Ohno H, Niki Y, Shibuya K, Miyazaki Y. Dendritic cell-based immunization ameliorates pulmonary infection with highly virulent Cryptococcus gattii. Infect Immun. 83(4):1577-86, 2015.
  4. Ozeki Y, Igarashi M, Doe M, Tamaru A, Kinoshita N, Ogura Y, Iwamoto T, Sawa R, Umekita M, Enany S, Nishiuchi Y, Osada-Oka M, Hayashi T, Niki M, Tateishi Y, Hatano M, Matsumoto S. A New Screen for Tuberculosis Drug Candidates Utilizing a Luciferase-Expressing Recombinant Mycobacterium bovis Bacillus Calmette-Gueren. PLoS One. 10(11):e0141658, 2015.
  5. Yoshida H, Seki M, Umeyama T, Urai M, Kinjo Y, Nishi I, Toyokawa M, Kaneko Y, Ohno H, Miyazaki Y, Tomono K. Invasive pulmonary aspergillosis due to Aspergillus lentulus: Successful treatment of a liver transplant patient. J Infect Chemother. 21(6):479-81, 2015.
  6. Asano M, Mizutani M, Nagahara Y, Inagaki K, Kariya T, Masamoto D, Urai M, Kaneko Y, Ohno H, Miyazaki Y, Mizuno M, Ito Y. Successful Treatment of Cryptococcus laurentii Peritonitis in a Patient on Peritoneal Dialysis. Intern Med. 54(8):941-4, 2015.

2014年度

  1. Kimura Y et al. Case of trichomycosis axillaris caused by Corynebacterium propinquum. J Dermatol. 41(5):467-469, 2014.
  2. Nishiuchi Y et al. Direct detection of Mycobacterium avium in environmental water and scale samples by loop-mediated isothermal amplification. J Water Health. 12(2):211-219, 2014.
  3. Fujii S et al. Serological surveillance development for tropical infectious diseases using simultaneous microsphere-based multiplex assays and finite mixture models. PLoS Negl Trop Dis. 8(7):e3040, 2014.
  4. Otani S et al. Biased hypermutation occurred frequently in a gene inserted into the IC323 recombinant measles virus during its persistence in the brains of nude mice. Virology. 462-463:91-97, 2014.
  5. Urai M et al. Potent drugs that attenuate anti-Candida albicans activity of fluconazole and their possible mechanisms of action. J Infect Chemother. 20(10):612-615, 2014.
なお、本研究の一部は、以下の研究費の支援を受けて実施された。
  • 新興・再興感染症に対する革新的医薬品等開発推進研究事業「薬剤耐性菌対策に資する診断法・治療法等の開発研究」(2017〜2019、2020)
  • 新興・再興感染症に対する革新的医薬品等開発研究事業「酵母様真菌感染症の病原性解明と疫学・診断法・制御法の研究」
  • 若手研究(B)「シクロオキシゲナーゼ阻害剤の抗真菌薬抵抗性誘導メカニズムの解明」
  • 基盤研究(C)「薬剤耐性アシネトバクターのゲノム疫学解析による耐性機構の解明」(2017〜2019)
  • 基盤研究(C)「抗菌物質ハンティング〜多剤耐性菌を打ち破る新奇抗菌物質の獲得〜」
  • 基盤研究(C)「続・抗菌物質ハンティング〜多剤耐性菌を打ち破る新奇抗菌物質の獲得〜」(2017〜2019)
  • 基盤研究(C)「難診断深在性真菌症の早期診断法の開発」(2016〜2018)
  • 基盤研究(C)「特異抗体を用いた深在性真菌症の新規画像診断法の開発」(2019〜)
  • ファイザーアカデミックコントリビューションズ(2014〜2019)
  • サイドメニューコンテンツ

    オンライン細菌学講座

    ILOHA